Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors

References

• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376(9746):1094–108.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68(12):1856–62.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Mariette X, Montecucco C, Monteagudo-Sáez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66(6):732–9.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552–63.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015;74(6):1037–44.
   PubMed Web of Science ®Google Scholar
• Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, et al. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52. Mod Rheumatol. 2015;25:31–7.
   PubMed Web of Science ®Google Scholar
• Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med. 1999;133(6):566–74.
   PubMed Web of Science ®Google Scholar
• Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factorkappaB activation in cultured human synovial cells. J Rheumatol 2001;28:2591–6.
   PubMed Web of Science ®Google Scholar
• Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res. 2002;51(4):188–94.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology. 2003;42(11):1365–71.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2013;23(3):430–9.
   PubMed Web of Science ®Google Scholar
• Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Iguratimod-Clinical Study Groupet al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2014;24(3):410–8.
   PubMed Web of Science ®Google Scholar
• Yoshikawa A, Yoshida S, Kimura Y, Tokai N, Fujiki Y, Kotani T, et al. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: a retrospective study. Mod Rheumatol. 2018;28(2):227–34.
   PubMed Web of Science ®Google Scholar
• Ebina K, Miyama A, Tsuboi H, Kaneshiro S, Nishikawa M, Owaki H, et al. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Mod Rheumatol. 2019;29(4):581–8.
   PubMed Web of Science ®Google Scholar
• Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, et al. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) Study. Mod Rheumatol. 2012;22(3):339–45.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum. 2011;63(1):37–42.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–35.
   PubMed Web of Science ®Google Scholar
• Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013;9(3):154–63.
   PubMed Web of Science ®Google Scholar
• Nishina N, Kaneko Y, Kameda H, Kuwana M, Takeuchi T. Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin Rheumatol. 2013;32(11):1661–6.
   PubMed Web of Science ®Google Scholar
• Mouchlis VD, Dennis EA. Membrane and inhibitor interactions of intracellular phospholipases A2. Adv Biol Regul. 2016;61:17–24.
   PubMedGoogle Scholar
• Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1806–12.
   PubMed Web of Science ®Google Scholar
• Michaels RM, Reading JC, Beezhold DH, Ward JR. Serum phospholipase A2 activity in patients with rheumatoid arthritis before and after treatment with methotrexate, auranofin, or combination of the two. J Rheumatol 1996;23(2):226–9.
   PubMed Web of Science ®Google Scholar
• Mucke HA. Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today. 2012;48(9):577–86.
   PubMed Web of Science ®Google Scholar
• Appleby SB, Ristimäki A, Neilson K, Narko K, Hla T. Structure of the human cyclooxygenase-2 gene. Biochem J.1994;302(3):723–7.
   PubMedGoogle Scholar
• Crofford LJ, Tan B, McCarthy CJ, Hla T. Involvement of nuclear factor κB in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum. 1997;40(2):226–36.
   PubMed Web of Science ®Google Scholar
• Asai S, Hayashi M, Hanabayashi M, Kanayama Y, Takemoto T, Yabe Y, et al. Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study. Mod Rheumatol 2019;8:1–7.
   Google Scholar
• Kremer JM, Rigby W, Singer NG, Birchwood C, Gill D, Reiss W, et al. Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized, controlled trial. Arthritis Rheumatol. 2018;70(8):1200–8.
   PubMed Web of Science ®Google Scholar
• Mori S, Yoshitama T, Hidaka T, Hirakata N, Ueki Y. Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study). Ann Rheum Dis. 2015;74(3):627–30.
   PubMed Web of Science ®Google Scholar
• Castagné B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis. PLOS One. 2019 ;14(8):e0220178.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75(11):1917–23.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kremer JM, van Vollenhoven RF, Alten R, Scali JJ, Kelman A, et al. Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheumatol. 2017;69(9):1751–61.
   PubMed Web of Science ®Google Scholar
• Mori S. Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritis. Mod Rheumatol. 2012;22(6):947–50.
   PubMed Web of Science ®Google Scholar